Sunitinib Induced Hypocalcaemia During Treatment of Pancreatic Neuroendocrine Tumors (pNETs)
#1014
Introduction: Sunitinib is an oral multitargeted tyrosine kinase inhibitor used for pNET treatment.
Aim(s): To investigate the prevalence of hypocalcemia during treatment.
Materials and methods: Three out of 12 patients with pNETs treated with sunitinib developed grade 1, 2 and 4 hypocalcemia.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Alexandraki K, Karnezis J, Kaltsatou M, Chatzelis E, Tsoli M,
Keywords: Sunitinib, pNET, hypocalcemia,
To read the full abstract, please log into your ENETS Member account.